Finance
UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT
Published by Global Banking & Finance Review®
Posted on January 14, 2026
1 min readLast updated: January 19, 2026
Quick Summary
Oxford Biomedica has confirmed receiving an unsolicited cash offer from EQT funds for all its shares, marking a significant interest in the biotech sector.
Oxford Biomedica Acknowledges Unsolicited Cash Offer from EQT Funds
Oxford Biomedica's Unsolicited Offer
Jan 14 (Reuters) - British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares.
Details of the Offer
(Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona)
Key Takeaways
- •Oxford Biomedica received an unsolicited offer from EQT funds.
- •The offer is for all shares of Oxford Biomedica.
- •This move highlights interest in the biotech sector.
- •The offer details were reported by Reuters.
- •EQT funds are managed by a global investment organization.
Frequently Asked Questions about UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT
1What is an unsolicited bid?
An unsolicited bid is an offer made to purchase a company’s shares without the prior agreement or invitation from the company's management.
2What is equity?
Equity refers to the ownership interest in a company, represented by shares of stock. It signifies the value of an owner's stake in the business.
3What are funds managed by EQT?
EQT refers to a private equity firm that manages investments in various sectors, focusing on creating value through operational improvements and strategic growth.
4What is a cash offer?
A cash offer is a proposal to purchase shares of a company for cash, as opposed to stock or other forms of payment.
